Home›Companies›Biotech & Pharma›Cloverleaf Bio

Cloverleaf Bio, Inc.

Develops RNA-based cancer treatments for people with cancer.

Updated Nov 9, 2026·Latest SEC filing Sep 9, 2026·Suggest an edit

About Cloverleaf Bio

Cloverleaf Bio is a private company based in New Haven, Connecticut, incorporated in 2023 in Delaware. It has reported $14,799,988 raised in one offering on Form D since September 2026.

Funding Rounds (SEC Form D)

First saleFiled with SECAmount soldInvestorsAvg. checkTermsFiling
Aug 24, 2026Sep 9, 2026$14,799,988of $29.5M target12$1.2MEquityRule 506(b)Form D ↗

First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.

Leadership Team

Executive officers and directors listed on Cloverleaf Bio's Form D filed Sep 9, 2026.

Sources

  1. SECCloverleaf Bio, Inc. filing history
  2. InvestorDraper Associates portfolio page
  3. PressForbes profile of Cole Lewis